drugset / Trial / NCT03290703

A Study to Investigate the Effect of Formulation, Food, and Rabeprazole on the Pharmacokinetics (PK) of GDC-0853 in Healthy Participants

NCT03290703

Phase 1 Completed 63 enrolled Genentech, Inc.
RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study is to evaluate the PK of GDC-0853 following changes to formulation and in the presence or absence of food, the proton pump inhibitor (rabeprazole), or both. This will be a 3-part open-label randomized study conducted in healthy adult participants. Approximately 63 subjects will be enrolled in this study.

Timeline

Start
2017-04-18
Primary completion
2018-10-25
Completion
2018-10-25

Drugs

EvaluationDrugModalityDoseRoute
Subject Fenebrutinib Small molecule Oral
Subject Rabeprazole Small molecule 20 mg

Indications

No indication recorded.